Recent Advances In Quinoxaline Derivatives (2020–2025) Green Synthesis Approaches And Anticancer Potential

Quinoxaline derivatives have gained considerable importance in medicinal chemistry due to their diverse pharmacological activities and broad therapeutic applications. During the period from 2020 to 2025, extensive research has focused on the development of quinoxaline-based compounds using environmentally sustainable synthetic methods and evaluating their anticancer potential. Quinoxaline is a nitrogen-containing fused heterocyclic scaffold whose structural versatility allows the incorporation of various functional groups, leading to compounds with enhanced biological activity and selectivity. Recent scientific advances indicate that quinoxaline derivatives exhibit promising anticancer properties against several cancer types, including breast, lung, liver, colon, and cervical cancers.

The growing concern regarding environmental pollution and hazardous chemical waste has encouraged researchers to adopt green chemistry principles in quinoxaline synthesis. Traditional synthetic procedures often involve toxic solvents, harsh reaction conditions, and long reaction times. To overcome these limitations, modern green approaches such as microwave-assisted synthesis, solvent-free reactions, ultrasound irradiation, aqueous-phase synthesis, and multicomponent reactions have been widely explored. These techniques provide several advantages, including higher yields, reduced energy consumption, shorter reaction times, and minimal environmental impact. Among these methods, microwave-assisted synthesis has become especially significant because it accelerates chemical reactions efficiently while improving product purity. Likewise, solvent-free condensation reactions between o-phenylenediamine and diketones have demonstrated excellent atom economy and sustainability.

Recent studies have also highlighted the role of reusable catalysts and nanotechnology in green quinoxaline synthesis. Magnetic nanoparticles, silica-supported catalysts, ionic liquids, and deep eutectic solvents have shown remarkable catalytic efficiency under mild conditions. These catalytic systems can often be recovered and reused multiple times, reducing operational costs and chemical waste generation. Water has additionally emerged as an eco-friendly reaction medium due to its non-toxic and inexpensive nature. Such environmentally benign methods support the principles of sustainable pharmaceutical development and industrial green chemistry.

Apart from synthetic advancements, quinoxaline derivatives have shown remarkable progress as anticancer agents through multiple mechanisms of action. Many newly synthesized compounds exhibit cytotoxic effects by inducing apoptosis, arresting the cell cycle, inhibiting angiogenesis, and suppressing tumor cell proliferation. Several quinoxaline analogs function as inhibitors of important molecular targets such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and phosphoinositide 3-kinase (PI3K), which are involved in cancer progression and metastasis. Some derivatives also interfere with DNA replication and topoisomerase activity, leading to selective destruction of cancer cells.

Hybrid molecules containing quinoxaline linked with triazoles, chalcones, or imidazoles have demonstrated synergistic biological effects and improved activity against drug-resistant cancer cells. In addition, computational techniques such as molecular docking and in silico ADMET studies have accelerated the identification of potent lead molecules with improved pharmacokinetic properties and reduced toxicity.

Although quinoxaline derivatives demonstrate strong therapeutic potential, certain challenges remain regarding bioavailability, metabolic stability, and selective targeting. Future research is expected to focus on nanoformulations, targeted drug delivery systems, and artificial intelligence-assisted drug design to improve clinical applicability. Overall, recent advances between 2020 and 2025 confirm that quinoxaline derivatives represent a promising class of heterocyclic compounds for sustainable synthesis and anticancer drug discovery.